AlphAIAlphAI — Financial news for AI agents
investing.com$GKOS

Needham raises Glaukos stock price target on Epioxa strength

Needham raised Glaukos (NYSE:GKOS) price target to $251, citing strong Q3 2026 results and raised guidance. The stock is up 135% in a year. Mizuho and Truist also raised targets. GKOS reported Q3 earnings beat with $211M in sales, up 58% YoY.

Original reporting
investing.com
Published Oct 29, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishMed
01

Why it matters

Analyst target hikes reflect confidence in sustained growth, but the stock already trades near historic highs.

02

Market read

Strong earnings and upgraded targets could trigger buying interest in GKOS.

03

What to watch

Potential supply‑chain constraints for Epioxa rollout.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Glaukos reported a 58% YoY revenue increase and turned profitable in Q3 2026, driven by its Epioxa platform.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Needham raised its price target on Glaukos to $251 and reported Q3 earnings beat with $0.47 EPS and $211M revenue.

Expected impact

likely upward pressure as investors price in higher targets and strong earnings.

Evidence & confidence

Target raise of 25% and earnings beat are fresh, material information for a mid‑cap med‑tech stock.

Market effects

Sector

Positive earnings may lift other glaucoma‑device makers.

Regional

U.S. med‑tech sector could see modest gains.

Global

Limited to U.S. equities.

Counterpoint

What could challenge this read

Valuation may already be stretched; price could stall.

Key entities

  • company
    Glaukos Corporation

    Medical technology firm focused on glaucoma treatments.

  • analyst
    Needham

    Equity research firm that raised the price target.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com